Is a complete IMUX research report available?

No complete published report is available for Immunic, Inc. (IMUX) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Immunic, Inc. (IMUX)

NASDAQ: IMUX · USD

$13.4

-0.89 (-6.2%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-25 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first IMUX analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	182.4M
Net income (ttm)	-104.3M
EPS (ttm)	-$5.07
Shares out	13.6M
Volume	155,828
Beta	1.38
Price target	$43.2	+222.8%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -104.3M
EPS (ttm): -$5.07
Market cap: 182.4M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All IMUX indicators

Market & fundamental data

Available fields

180

Groups with data

Currency

USD

Showing 180 of 180 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001280776
Company name	Immunic, Inc.
Country	United States
Country code	US
Cusip	4525EP200
Employees	95
Employees Change	3%
Employees Change Percent	3.26
Enterprise value	$-3.8M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US4525EP2001
Last refreshed	2026-07-25
Market cap	$182.4M
Market cap category	Micro-Cap
Price	$13.39
Price currency	USD
Sector	Healthcare
Sector PE	44.8
Sector PE Fwd	23.59
Sic	2834
Symbol	IMUX
Website	https://imux.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-57.18%
FCF yield	-44.65%
P/B ratio	1.29x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-104.3M
Net Income Growth Years	1%
Profit Per Employee	$-1.1M
ROA	-65.18
Roa5y	-93.3
ROCE	-72.43
ROE	-142.9
Roe5y	-474.8
ROIC	-93.01

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	34.33%
Cagr3y	-18.57%
Cagr5y	-31.95%
EPS Growth Quarters	2
EPS Growth Years	4
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$189.7M
Cash	$186.6M
Current Assets	$188.8M
Current Liabilities	$38.4M
Debt	$421,000
Debt Equity	$0
Equity	$151.2M
Liabilities	$38.5M
Long Term Assets	$983,000
Long Term Liabilities	$146,000
Net Cash	$186.2M
Net Cash By Market Cap	$102
Net Cash Growth	1,297.01%
Net Debt Equity	$-1.23
Tangible Book Value	$151.2M
Tangible Book Value Per Share	$11.1
WACC	11.79

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	4.92
Net Working Capital	$-36M
Quick ratio	4.87
Working Capital	$150.4M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-103.28%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	34.3%
200-day SMA	9.97
3Y total return	-46.01%
50-day SMA	14.05
50-day SMA vs 200-day SMA	50over200
5Y total return	-85.4%
All Time High	289.9
All Time High Change	-95.38%
All Time High Date	2019-04-15
All Time Low	5.06
All Time Low Change	164.52%
All Time Low Date	2025-12-30
ATR	0.94
Beta	1.38
Beta1y	0.41
Beta2y	0.9
Ch YTD	150.9
High	14.38
High52	15.84
High52 Date	2026-07-17
High52ch	-15.47%
Low	13.2
Low52	5.06
Low52 Date	2025-12-30
Low52ch	164.52%
Ma50ch	-4.68%
Price vs 200-day SMA	34.36%
RSI	37.1
RSI Monthly	49.22
RSI Weekly	56.66
Sharpe ratio	0.72x
Sortino ratio	1.2
Total Return	-103.28%
Tr YTD	150.9
Tr1m	-11.15%
Tr1w	-11.68%
Tr3m	45.81%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	10
Analyst Count Top	5
Analyst Price Target Top	$43.25
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-1.19
Operating Income	$-109.6M
Price target	$43.22
Price Target Change	$223
Price Target Change Top	$223

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	11,841,995%
Float Percent	86.94%
Shares Insiders	1.62%
Shares Institutions	40.28%
Shares Out	13,621,526
Shares Qo Q	55.09%
Shares Yo Y	103.28%
Short Float	13.4%
Short Ratio	7.2
Short Shares	11.65

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-92.7M
Average Volume	164,784.5x
Bv Per Share	11.1
CAPEX	$-116,000
Ch1m	-11.15
Ch1w	-11.68
Ch1y	34.3
Ch3m	45.81
Ch3y	-46.01
Ch5y	-85.4
Ch6m	94.82
Change	-6.23%
Change From Open	-6.88
Close	14.28
Days Gap	0.7
Depreciation Amortization	158,000
Dollar Volume	2,086,536.9
Earnings Date	2026-08-06
Earnings Time	bmo
EBIT	$-109.6M
EBITDA	$-109.5M
EPS	$-5.07
F Score	2
FCF	$-81.4M
FCF EV Yield	2,134.49x
FCF Per Share	$-5.98
Financing CF	254,219,000
Fiscal Year End	December
Founded	2,016
Investing CF	-116,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-13
Last Report Date	2026-03-31
Last Split Date	2026-04-27
Last Split Type	Reverse
Last10k Filing Date	2026-02-26
Ma150	10.79
Ma150ch	24.06%
Ma20	14.89
Ma20ch	-10.07%
Net CF	172,325,000
Next Earnings Date	2026-08-06
Open	14.38
Optionable	Yes
Position In Range	16.1
Post Close	13.39
Postmarket Change Percent	-2.09
Postmarket Price	$13.11
Ppne	983,000
Price Date	2026-07-24
Ptbv Ratio	1.21
Relative Volume	0.95x
Share Based Comp	11,287,000
Tr6m	94.82%
Us State	New York
Volume	155,828

Immunic, Inc. (IMUX)

Coverage state: Market snapshot only — no published research

Generate the first IMUX analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · IMUX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All IMUX indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on IMUX

Frequently asked questions